Cargando…
Discovery of a novel RORγ antagonist with skin-restricted exposure for topical treatment of mild to moderate psoriasis
Clinical success of IL-17/IL-23 pathway biologics for the treatment of moderate to severe psoriasis suggests that targeting RORγt, a master regulator for the proliferation and function of Th17 cells, could be an effective alternative. However, oral RORγ antagonists (VTP43742, TAK828) with high syste...
Autores principales: | Liu, Suxing, Liu, Dong, Shen, Ru, Li, Di, Hu, Qiyue, Yan, Yinfa, Sun, Jiakang, Zhang, Fengqi, Wan, Hong, Dong, Ping, Feng, Jun, Zhang, Rumin, Li, Jing, Zhang, Lianshan, Tao, Weikang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8080595/ https://www.ncbi.nlm.nih.gov/pubmed/33911101 http://dx.doi.org/10.1038/s41598-021-88492-1 |
Ejemplares similares
-
A Novel CD73 Inhibitor SHR170008 Suppresses Adenosine in Tumor and Enhances Anti-Tumor Activity with PD-1 Blockade in a Mouse Model of Breast Cancer
por: Liu, Suxing, et al.
Publicado: (2021) -
Development of a Topical Treatment for Psoriasis Targeting RORγ: From Bench to Skin
por: Smith, Susan H., et al.
Publicado: (2016) -
Targeting castration-resistant prostate cancer with a novel RORγ antagonist elaiophylin
por: Zheng, Jianwei, et al.
Publicado: (2020) -
SHR1032, a novel STING agonist, stimulates anti-tumor immunity and directly induces AML apoptosis
por: Song, Chunying, et al.
Publicado: (2022) -
Digoxin, an Overlooked Agonist of RORγ/RORγT
por: Karaś, Kaja, et al.
Publicado: (2019)